Estrago-Franco M Fernanda, Moustafa M Tarek, Riazi-Esfahani Mohammad, Sapkal Ashish U, Piche-Lopez Rhina, Patil A Jayaprakash, Sharma Ashish, Falatoonzadeh Payam, Chwa Marilyn, Luczy-Bachman Georgia, Kuppermann Baruch D, Kenney M Cristina
Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; Clinica Dres Estrago, Corrientes, Argentina.
Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA; Ophthalmology Department, Minia University, Egypt.
J Ophthalmic Vis Res. 2016 Oct-Dec;11(4):385-393. doi: 10.4103/2008-322X.194091.
To identify inhibitors that could effectively lower reactive oxygen/nitrogen species (ROS/RNS), complement and inflammatory cytokine levels induced by Benzo(e)pyrene [B(e)p], an element of cigarette smoke, in human retinal pigment epithelial cells (ARPE-19) .
ARPE-19 cells were treated for 24 hours with 200 μM, 100 μM, and 50 μM B(e)p or DMSO (dimethyl sulfoxide)-equivalent concentrations. Some cultures were pre-treated with ROS/RNS inhibitors (NG nitro-L-arginine, inhibits nitric oxide synthase; Apocynin, inhibits NADPH oxidase; Rotenone, inhibits mitochondrial complex I; Antimycin A, inhibits mitochondria complex III) and ROS/RNS levels were measured with a fluorescent H DCFDA assay. Multiplex bead arrays were used to measure levels of Interleukin-6 (IL-6), Interleukin-8 (IL-8), Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Transforming Growth Factor alpha (TGF-α) and Vascular Endothelial Growth Factor (VEGF). IL-6 levels were also measured by an enzyme-linked immunosorbent assay. Real-time qPCR analyses were performed with primers for C3 (component 3), CFH (inhibits complement activation), CD59 (inhibitor of the complement membrane attack complex (MAC)) and CD55/DAF (accelerates decay of target complement target proteins).
The ARPE-19 cultures treated with B(e)p showed significantly increased ROS/RNS levels ( < 0.001), which were then partially reversed by 6 μM Antimycin A (19%, = 0.03), but not affected by the other ROS/RNS inhibitors. The B(e)p treated cultures demonstrated increased levels of IL-6 (33%; = 0.016) and GM-CSF (29%; = 0.0001) compared to DMSO-equivalent controls, while the expression levels for components of the complement pathway (C3, CFH, CD59 and CD55/DAF) were not changed.
The cytotoxic effects of B(e)p include elevated ROS/RNS levels along with pro-inflammatory IL-6 and GM-CSF proteins. Blocking the Qi site of cytochrome c reductase (complex III) with Antimycin A led to partial reduction in B(e)p induced ROS production. Our findings suggest that inhibitors for multiple pathways would be necessary to protect the retinal cells from B(e)p induced toxicity.
鉴定能够有效降低香烟烟雾成分苯并芘[B(e)p]诱导的人视网膜色素上皮细胞(ARPE - 19)中活性氧/氮物种(ROS/RNS)、补体和炎性细胞因子水平的抑制剂。
将ARPE - 19细胞用200μM、100μM和50μM的B(e)p或二甲基亚砜(DMSO)等效浓度处理24小时。一些培养物用ROS/RNS抑制剂(NG - 硝基 - L - 精氨酸,抑制一氧化氮合酶;白杨素,抑制NADPH氧化酶;鱼藤酮,抑制线粒体复合物I;抗霉素A,抑制线粒体复合物III)进行预处理,并用荧光H DCFDA测定法测量ROS/RNS水平。使用多重微珠阵列测量白细胞介素 - 6(IL - 6)、白细胞介素 - 8(IL - 8)、粒细胞 - 巨噬细胞集落刺激因子(GM - CSF)、转化生长因子α(TGF - α)和血管内皮生长因子(VEGF)的水平。IL - 6水平也通过酶联免疫吸附测定法进行测量。用C3(成分3)、CFH(抑制补体激活)、CD59(补体膜攻击复合物(MAC)的抑制剂)和CD55/DAF(加速靶补体靶蛋白衰变)的引物进行实时定量PCR分析。
用B(e)p处理的ARPE - 19培养物显示ROS/RNS水平显著升高(<0.001),然后被6μM抗霉素A部分逆转(19%,P = 0.03),但不受其他ROS/RNS抑制剂影响。与DMSO等效对照相比,用B(e)p处理的培养物显示IL - 6(33%;P = 0.016)和GM - CSF(29%;P = 0.0001)水平升高,而补体途径成分(C3、CFH、CDS9和CD55/DAF)的表达水平未改变。
B(e)p的细胞毒性作用包括ROS/RNS水平升高以及促炎IL - 6和GM - CSF蛋白。用抗霉素A阻断细胞色素c还原酶(复合物III)的Q位点导致B(e)p诱导的ROS产生部分降低。我们的研究结果表明,需要多种途径的抑制剂来保护视网膜细胞免受B(e)p诱导的毒性。